NCT00107432View on ClinicalTrials.gov

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

June 30, 2007

Conditions
Epithelial MesotheliomaRecurrent Malignant MesotheliomaSarcomatous MesotheliomaStage IA Malignant MesotheliomaStage IB Malignant MesotheliomaStage II Malignant MesotheliomaStage III Malignant MesotheliomaStage IV Malignant Mesothelioma
Interventions
DRUG

sorafenib tosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

60606

Cancer and Leukemia Group B, Chicago

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00107432 - Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. | Biotech Hunter | Biotech Hunter